Scientist man in white gowns stands in a research lab

Research

Science can improve health and wellbeing in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.

As GSK and through our heritage companies, we have a 150-year legacy of applying science to discover and develop new medicines, vaccines and consumer healthcare products that help to transform lives.

More than 11,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products.

A Canadian R&D Leader

GSK has invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines R&D, ranking it among the top 10 contributors to R&D in Canada across all industries. In 2016 alone, GSK in Canada invested over $62 million to R&D.

Clinical Studies

  • In 2017, GSK invested $13.2 million in conducting 31 clinical trials across Canada involving 1,921 subjects.
  • In 2017, GSK supported 16 Investigator Sponsored Studies with physicians across Canada. 
  • In 2017, GSK sponsored approximately 30 Canadian research projects, focused on health economics and outcomes research, to support the scientific understanding of our medicines and vaccines in Canada.

Supporting R&D Innovation in Canada

To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organisations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.

In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies.  GSK works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as MaRS Innovation, the Centre for Drug Research and Development (CDRD), and the Quebec Consortium for Drug Development (CQDM), to identify exciting new opportunities in drug discovery and development for potential collaboration with GSK.

Click here to see our current areas of interest.  For more information, please contact Amyn Sayani, (905) 819 3185 or Amyn.P.Sayani@gsk.com.

Find out about the main areas of science we are focusing on, how we conduct our research, what drives our R&D operations, and view our product pipeline.